Evaluation of the Pharmacokinetics and Pharmacodynamics of Hydroxychloroquine in COVID-19 Intensive Care Unit Patients
Status:
Terminated
Trial end date:
2020-05-28
Target enrollment:
Participant gender:
Summary
To date, no treatment has demonstrated clinical efficacy on COVID 19. However, several
therapeutic strategies are being considered and are being evaluated in numerous clinical
trials. Among these strategies, the use of hydroxychloroquine (HCQ) seems promising. There is
very little information on how to precisely administer hydroxychloroquine to patients
infected with SARS-CoV-2 in intensive care, which may be responsible for side effects, some
of which are potentially serious. In addition, this treatment has a long half-life which
increases the risk of accumulation and therefore toxicity. In view of the lack of knowledge
on the pharmacokinetic / pharmacodynamic properties of hydroxychloroquine in intensive care
patients infected with SARS-CoV-2, we propose to perform a prospective multicenter cohort
study in order to collect the biological data necessary for this evaluation.
Phase:
Phase 3
Details
Lead Sponsor:
Centre Hospitalier Universitaire de Saint Etienne
Collaborator:
CHU Saint-Etienne - Laboratoire de Pharmacologie - Toxicologie - Gaz du sang